The Program in Radiation Biology is focused on ways in which the effectiveness of radiotherapy canincrease local tumor control and survival of cancer patients. Three different approaches are beingpursued to achieve this goal: 1) Development of pharmacologic and biologic agents to combine withradiotherapy and chemotherapy to improve local tumor control and prevent metastatic spread. 2)Development of new approaches and clinical trials to administer radiotherapy. 3) The identification ofgenetic determinants that influence the tumor response to radiation or the combination of chemotherapyand radiation using yeast and mammalian genetics. The research of program members has resulted in aseries of important findings that include the regulation of stem cell differentiation by hypoxia,identifying a serum biomarker for tumor hypoxia, developing hypoxic specific cytotoxins for cancertherapy, identifying new genes that are essential for DNA repair and adaptation to stress, defining therole of p53 in global genomic DNA repair, generation of mouse models to dissect the role of p53transactivation and p53 target genes in in vivo stress responses, the use of radiosurgery to treat pancreaticcancer, liver, lung and prostate cancer, and developing molecular and functional imaging techniques todirect the delivery of radiotherapy. The 23 program members representing the School of Medicine andDepartment of Biological Sciences in the School of Humanities and Sciences are highly motivated todevelop new targeted therapeutics to combine with radiotherapy and are well supported by twoprogram project grants and $4.3 million in NCI funding. During the last five years, the program memberspublished 188 papers. With the support of the Cancer Center, the role of Radiation Biology in tumorimmunity, stem cell recruitment and differentiation, and functional imaging will be further developedand expanded. In particular, the Cancer Center will greatly aid in translating many of the laboratorybasedfindings to increase the effectiveness of radiotherapy into the clinic.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
1P30CA124435-01
Application #
7438430
Study Section
Subcommittee G - Education (NCI)
Project Start
2007-06-04
Project End
2010-05-31
Budget Start
2007-06-04
Budget End
2008-05-31
Support Year
1
Fiscal Year
2007
Total Cost
$16,966
Indirect Cost
Name
Stanford University
Department
Type
DUNS #
009214214
City
Stanford
State
CA
Country
United States
Zip Code
94305
Pollom, Erqi L; Fujimoto, Dylann K; Han, Summer S et al. (2018) Newly diagnosed glioblastoma: adverse socioeconomic factors correlate with delay in radiotherapy initiation and worse overall survival. J Radiat Res 59:i11-i18
Nørgaard, Caroline Holm; Jakobsen, Lasse Hjort; Gentles, Andrew J et al. (2018) Subtype assignment of CLL based on B-cell subset associated gene signatures from normal bone marrow - A proof of concept study. PLoS One 13:e0193249
Im, Hogune; Rao, Varsha; Sridhar, Kunju et al. (2018) Distinct transcriptomic and exomic abnormalities within myelodysplastic syndrome marrow cells. Leuk Lymphoma 59:2952-2962
Huang, Min; Zhu, Li; Garcia, Jacqueline S et al. (2018) Brd4 regulates the expression of essential autophagy genes and Keap1 in AML cells. Oncotarget 9:11665-11676
Chiou, Shin-Heng; Dorsch, Madeleine; Kusch, Eva et al. (2018) Hmga2 is dispensable for pancreatic cancer development, metastasis, and therapy resistance. Sci Rep 8:14008
Breslow, David K; Hoogendoorn, Sascha; Kopp, Adam R et al. (2018) A CRISPR-based screen for Hedgehog signaling provides insights into ciliary function and ciliopathies. Nat Genet 50:460-471
Chu, Lisa W; Till, Cathee; Yang, Baiyu et al. (2018) Circadian genes and risk of prostate cancer in the prostate cancer prevention trial. Mol Carcinog 57:462-466
Patel, Manali I; Sundaram, Vandana; Desai, Manisha et al. (2018) Effect of a Lay Health Worker Intervention on Goals-of-Care Documentation and on Health Care Use, Costs, and Satisfaction Among Patients With Cancer: A Randomized Clinical Trial. JAMA Oncol 4:1359-1366
Trieu, Vanessa; Pinto, Harlan; Riess, Jonathan W et al. (2018) Weekly Docetaxel, Cisplatin, and Cetuximab in Palliative Treatment of Patients with Squamous Cell Carcinoma of the Head and Neck. Oncologist 23:764-e86
Kuonen, François; Surbeck, Isabelle; Sarin, Kavita Y et al. (2018) TGF?, Fibronectin and Integrin ?5?1 Promote Invasion in Basal Cell Carcinoma. J Invest Dermatol 138:2432-2442

Showing the most recent 10 out of 322 publications